Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, compares the efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in patients with Waldenström’s macroglobulinemia. Matching-adjusted indirect comparisons (MAIC) of data from the ASPEN trial (NCT03053440) showed that zanubrutinib achieved significantly longer progression-free survival (PFS) in comparison to dexamethasone-rituximab-cyclophosphamide in patients with Waldenström’s macroglobulinemia. Compared to bendamustine-rituximab (BR), zanubrutinib demonstrated significantly longer PFS, overall survival (OS) and lower incidences of neutropenia in patients with Waldenström’s macroglobulinemia. Dr Castillo gives an overview of these findings and comments on implications for clinical practice. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
13 июн 2021
